drugset / Trial / NCT00322231

A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)

NCT00322231

Phase 3 Completed 101 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindPrevention

Summary

The purpose of this study is to determine whether the investigational zoster vaccine, is generally well tolerated when administered to participants with a history of herpes zoster.

Timeline

Start
2006-05
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Varivax Vaccine 0.65 ml Subcutaneous

Indications